Adamant Biomedical Investments’s Clovis Oncology, Inc. CLVS Stock Holding History

Adamant Biomedical Investments’s Portfolio CLVS Stock Details CLVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	$2.8M	Buy	+50,000	New	+$2.63M	0.67%	53

Other funds holding CLVS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Adamant Biomedical Investments's CLVS Position: Q4 2014 in Review

Adamant Biomedical Investments opened a new position in Clovis Oncology, Inc. (CLVS) in Q4 2014: 50,000 shares worth $2.8M. The stake represents 0.67% of the portfolio and ranks #53 among its holdings.

143 funds tracked by Wall St. Rank hold CLVS as of Q4 2014.

Adamant Biomedical Investments held 50,000 shares of Clovis Oncology, Inc. worth $2.8M as of Q4 2014.
Clovis Oncology, Inc. was a new Adamant Biomedical Investments position in Q4 2014.
Clovis Oncology, Inc. made up 0.67% of Adamant Biomedical Investments's portfolio in Q4 2014, its #53 holding.
143 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.